March 02, 2021
The investigational neuromodulator, evaluated in clinical trials as a treatment for glabellar lines and as a combined therapy for glabellar, dynamic forehead, and lateral canthal lines, is quickly nearing an approval by the FDA.
February 25, 2021
Cancer staging systems for squamous cell carcinoma have helped improve dermatologists’ ability to accurately stage the cancer, according to one expert.
February 17, 2021
In the Moderna coronavirus disease 2019 (COVID-19) vaccine trials, 3 participants reported facial or lip swelling after receiving the vaccine. ASDS guidelines state that patients with a history of dermal filler injections should not void vaccinations
December 23, 2020
Findings from two recent pilot studies suggest 1927 nm fractional thulium fiber laser-assisted topical tranexamic acid delivery is a safe, effective melasma treatment option.
December 22, 2020
A recent study found patients with high baseline cardiovascular risk who had taken ustekinumab were at increased risk for developing severe cardiovascular events following treatment.
December 18, 2020
Dermatologists should consider assessing melasma patients for increased vascularity and include antivascular treatments to improve outcomes among patients whose lesions have a vascular component.
December 08, 2020
Researchers are looking at treating blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematolymphoid malignancy, with investigational agents equipped with different mechanisms of action, including XmAb14045 and IMGN632.
November 12, 2020
A recently published article details the clinical and biological features, and patient outcomes of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematopoietic malignancy.
November 11, 2020
B-cell lymphoma-2 inhibitor venetoclax has shown in clinical studies to improve symptoms with minimal toxicity in patients with cutaneous blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer that can be rapidly fatal without treatment.
November 03, 2020
A majority of psoriasis patients in phase 3 clinical trials for biologics are white, says authors of a recent study. As ethnicity and race may play a role in response to biologics, researchers emphasize need for more diversity in clinical trials.
